Immunization with Single-Cycle SIV Significantly Reduces Viral Loads After an Intravenous Challenge with SIVmac239

Strains of simian immunodeficiency virus (SIV) that are limited to a single cycle of infection were evaluated for the ability to elicit protective immunity against wild-type SIVmac239 infection of rhesus macaques by two different vaccine regimens. Six animals were inoculated at 8-week intervals with 6 identical doses consisting of a mixture of three different envelope variants of single-cycle SIV (scSIV). Six additional animals were primed with a mixture of cytoplasmic domain-truncated envelope variants of scSIV and boosted with two doses of vesicular stomatitis virus glycoprotein (VSV G) trans-complemented scSIV. While both regimens elicited detectable virus-specific T cell responses, SIV-specific T cell frequencies were more than 10-fold higher after boosting with VSV G trans-complemented scSIV (VSV G scSIV). Broad T cell recognition of multiple viral antigens and Gag-specific CD4+ T cell responses were also observed after boosting with VSV G scSIV. With the exception of a single animal in the repeated immunization group, all of the animals became infected following an intravenous challenge with SIVmac239. However, significantly lower viral loads and higher memory CD4+ T cell counts were observed in both immunized groups relative to an unvaccinated control group. Indeed, both scSIV immunization regimens resulted in containment of SIVmac239 replication after challenge that was as good as, if not better than, what has been achieved by other non-persisting vaccine vectors that have been evaluated in this challenge model. Nevertheless, the extent of protection afforded by scSIV was not as good as typically conferred by persistent infection with live, attenuated SIV. These observations have potentially important implications to the design of an effective AIDS vaccine, since they suggest that ongoing stimulation of virus-specific immune responses may be essential to achieving the degree of protection afforded by live, attenuated SIV.

[1]  Jon Cohen Thumbs Down on Expensive, Hotly Debated Trial of NIH AIDS Vaccine , 2008, Science.

[2]  S. Hammer,et al.  HIV Vaccine Research: The Way Forward , 2008, Science.

[3]  John P. Moore,et al.  Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans , 2008, Nature Medicine.

[4]  R. Desrosiers,et al.  Vaccine Protection by Live, Attenuated Simian Immunodeficiency Virus in the Absence of High-Titer Antibody Responses and High-Frequency Cellular Immune Responses Measurable in the Periphery , 2008, Journal of Virology.

[5]  R. Sékaly The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? , 2008, The Journal of experimental medicine.

[6]  R. Steinbrook One step forward, two steps back--will there ever be an AIDS vaccine? , 2007, The New England journal of medicine.

[7]  J. Lifson,et al.  Comparison of Plasma Viremia and Antibody Responses in Macaques Inoculated with Envelope Variants of Single-Cycle Simian Immunodeficiency Virus Differing in Infectivity and Cellular Tropism , 2007, Journal of Virology.

[8]  D. Purcell,et al.  Killing Kinetics of Simian Immunodeficiency Virus-Specific CD8+ T Cells: Implications for HIV Vaccine Strategies1 , 2007, The Journal of Immunology.

[9]  R. Steinman,et al.  Atraumatic Oral Spray Immunization with Replication-Deficient Viral Vector Vaccines , 2007, Journal of Virology.

[10]  D. Burton,et al.  Fc receptor but not complement binding is important in antibody protection against HIV , 2007, Nature.

[11]  D. Watkins,et al.  Molecular typing of major histocompatibility complex class I alleles in the Indian rhesus macaque which restrict SIV CD8+ T cell epitopes , 2007, Immunogenetics.

[12]  M. Carrington,et al.  Mamu-B*08-Positive Macaques Control Simian Immunodeficiency Virus Replication , 2007, Journal of Virology.

[13]  Ryan D. Hernandez,et al.  Demographic Histories and Patterns of Linkage Disequilibrium in Chinese and Indian Rhesus Macaques , 2007, Science.

[14]  R. Desrosiers,et al.  Induction of a virus-specific effector–memory CD4+ T cell response by attenuated SIV infection , 2006, The Journal of experimental medicine.

[15]  B. Jia,et al.  Single-cycle SIV: a novel AIDS vaccine approach , 2006 .

[16]  D. O’Connor,et al.  Control of Simian Immunodeficiency Virus SIVmac239 Is Not Predicted by Inheritance of Mamu-B*17-Containing Haplotypes , 2006, Journal of Virology.

[17]  R. Steinman,et al.  Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. , 2006, Virology.

[18]  Jiang Fan,et al.  Vaccine-Induced Cellular Immune Responses Reduce Plasma Viral Concentrations after Repeated Low-Dose Challenge with Pathogenic Simian Immunodeficiency Virus SIVmac239 , 2006, Journal of Virology.

[19]  D. Montefiori,et al.  Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge , 2006, The Journal of experimental medicine.

[20]  Gary J. Nabel,et al.  Preserved CD4+ Central Memory T Cells and Survival in Vaccinated SIV-Challenged Monkeys , 2006, Science.

[21]  M. Carrington,et al.  The High-Frequency Major Histocompatibility Complex Class I Allele Mamu-B*17 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication , 2006, Journal of Virology.

[22]  J. Tartaglia,et al.  Improved Vaccine Protection from Simian AIDS by the Addition of Nonstructural Simian Immunodeficiency Virus Genes1 , 2006, The Journal of Immunology.

[23]  D. Watkins,et al.  Attenuation of Simian Immunodeficiency Virus SIVmac239 Infection by Prophylactic Immunization with DNA and Recombinant Adenoviral Vaccine Vectors Expressing Gag , 2005, Journal of Virology.

[24]  R. Desrosiers,et al.  Virion Envelope Content, Infectivity, and Neutralization Sensitivity of Simian Immunodeficiency Virus , 2005, Journal of Virology.

[25]  J. Lifson,et al.  Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS , 2005, Journal of medical primatology.

[26]  R. Desrosiers,et al.  Immunization of Macaques with Single-Cycle Simian Immunodeficiency Virus (SIV) Stimulates Diverse Virus-Specific Immune Responses and Reduces Viral Loads after Challenge with SIVmac239 , 2005, Journal of Virology.

[27]  R. Desrosiers,et al.  Impact of Nef-Mediated Downregulation of Major Histocompatibility Complex Class I on Immune Response to Simian Immunodeficiency Virus , 2004, Journal of Virology.

[28]  V. Maino,et al.  Insufficient Production and Tissue Delivery of CD4+Memory T Cells in Rapidly Progressive Simian Immunodeficiency Virus Infection , 2004, The Journal of experimental medicine.

[29]  R. Desrosiers,et al.  A Novel Approach for Producing Lentiviruses That Are Limited to a Single Cycle of Infection , 2004, Journal of Virology.

[30]  R. Doms,et al.  Modulation of Env Content in Virions of Simian Immunodeficiency Virus: Correlation with Cell Surface Expression and Virion Infectivity , 2004, Journal of Virology.

[31]  Takahiro Hirata,et al.  Cytotoxic T Lymphocyte–based Control of Simian Immunodeficiency Virus Replication in a Preclinical AIDS Vaccine Trial , 2004, The Journal of experimental medicine.

[32]  J. Lifson,et al.  Optimization of intracellular cytokine staining for the quantitation of antigen-specific CD4+ T cell responses in rhesus macaques. , 2004, Journal of immunological methods.

[33]  B. Walker,et al.  Progress in Defining CD4 Helper Cell Responses in Chronic Viral Infections , 2003, The Journal of experimental medicine.

[34]  D. Burton,et al.  Assorted Mutations in the Envelope Gene of Simian Immunodeficiency Virus Lead to Loss of Neutralization Resistance against Antibodies Representing a Broad Spectrum of Specificities , 2003, Journal of Virology.

[35]  J. Heeney,et al.  Single-cycle immunodeficiency viruses provide strategies for uncoupling in vivo expression levels from viral replicative capacity and for mimicking live-attenuated SIV vaccines. , 2003, Virology.

[36]  R. Means,et al.  Determinants of Increased Replicative Capacity of Serially Passaged Simian Immunodeficiency Virus with nef Deleted in Rhesus Monkeys , 2003, Journal of Virology.

[37]  Hao Shen,et al.  Requirement for CD4 T Cell Help in Generating Functional CD8 T Cell Memory , 2003, Science.

[38]  M. Bevan,et al.  Defective CD8 T Cell Memory Following Acute Infection Without CD4 T Cell Help , 2003, Science.

[39]  Urs Christen,et al.  CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes , 2003, Nature.

[40]  Todd M. Allen,et al.  Expression of the Major Histocompatibility Complex Class I Molecule Mamu-A*01 Is Associated with Control of Simian Immunodeficiency Virus SIVmac239 Replication , 2003, Journal of Virology.

[41]  J. Lifson,et al.  SIVmac pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans , 2002, AIDS.

[42]  D. Watkins,et al.  Immunization of Rhesus Macaques with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen Induces Broad Simian Immunodeficiency Virus (SIV)-Specific T-Cell Responses and Reduces Initial Viral Replication but Does Not Prevent Disease Progression following Challenge with Pathogenic SIVmac239 , 2002, Journal of Virology.

[43]  Peter J. Dailey,et al.  The Liver Is a Major Organ for Clearing Simian Immunodeficiency Virus in Rhesus Monkeys , 2002, Journal of Virology.

[44]  P. Earl,et al.  Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. , 2002, Vaccine.

[45]  Z. Grossman,et al.  HIV preferentially infects HIV-specific CD4+ T cells , 2002, Nature.

[46]  E. Wherry,et al.  Vaccines: Effector and memory T-cell differentiation: implications for vaccine development , 2002, Nature Reviews Immunology.

[47]  John P. Moore,et al.  AIDS vaccine models: Challenging challenge viruses , 2002, Nature Medicine.

[48]  Henryk Mach,et al.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity , 2002, Nature.

[49]  D. Lu,et al.  Titration of an SIVmac251 stock by vaginal inoculation of Indian and Chinese origin rhesus macaques: transmission efficiency, viral loads, and antibody responses. , 2001, AIDS research and human retroviruses.

[50]  David Montefiori,et al.  An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants , 2001, Cell.

[51]  C. Cheng‐Mayer,et al.  Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.

[52]  Susan M. Kaech,et al.  Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells , 2001, Nature Immunology.

[53]  A. Roberts,et al.  Glycoprotein Exchange Vectors Based on Vesicular Stomatitis Virus Allow Effective Boosting and Generation of Neutralizing Antibodies to a Primary Isolate of Human Immunodeficiency Virus Type 1 , 2000, Journal of Virology.

[54]  A. Simon,et al.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. , 2000, Science.

[55]  F. Kirchhoff,et al.  Simian and Human Immunodeficiency Virus Nef Proteins Use Different Surfaces To Downregulate Class I Major Histocompatibility Complex Antigen Expression , 2000, Journal of Virology.

[56]  T. Quinn,et al.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. , 2000, The New England journal of medicine.

[57]  J. Mascola,et al.  Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.

[58]  Tahir A. Rizvi,et al.  Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.

[59]  D. Montefiori,et al.  Protection by Live, Attenuated Simian Immunodeficiency Virus against Heterologous Challenge , 1999, Journal of Virology.

[60]  R. Johnson,et al.  Characterization of SIV‐specific CD4 + T‐helper proliferative responses in macaques immunized with live‐attenuated SIV , 1999, Journal of medical primatology.

[61]  C. Pitcher,et al.  HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression , 1999, Nature Medicine.

[62]  Nancy Haigwood,et al.  Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell–free virions from blood plasma , 1999, Nature Medicine.

[63]  H. McClure,et al.  Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques , 1999, Nature Medicine.

[64]  Alan S. Perelson,et al.  Rapid Clearance of Simian Immunodeficiency Virus Particles from Plasma of Rhesus Macaques , 1999, Journal of Virology.

[65]  J. Altman,et al.  Viral Immune Evasion Due to Persistence of Activated T Cells Without Effector Function , 1998, The Journal of experimental medicine.

[66]  J. Lifson,et al.  Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. , 1998, AIDS research and human retroviruses.

[67]  D. Ho,et al.  Temporal Analyses of Virus Replication, Immune Responses, and Efficacy in Rhesus Macaques Immunized with a Live, Attenuated Simian Immunodeficiency Virus Vaccine , 1998, Journal of Virology.

[68]  R. Means,et al.  A role for carbohydrates in immune evasion in AIDS , 1998, Nature Medicine.

[69]  Todd M. Allen,et al.  Analysis of Gag-specific Cytotoxic T Lymphocytes in Simian Immunodeficiency Virus–infected Rhesus Monkeys by Cell Staining with a Tetrameric Major Histocompatibility Complex Class I–Peptide Complex , 1998, The Journal of experimental medicine.

[70]  A S Perelson,et al.  Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. , 1998, Science.

[71]  B. Everitt,et al.  Analysis of longitudinal data , 1998, British Journal of Psychiatry.

[72]  R. Means,et al.  Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus , 1997, Journal of virology.

[73]  R. Stebbings,et al.  Mechanisms of protection induced by attenuated simian immunodeficiency virus. I. Protection cannot be transferred with immune serum. , 1997, The Journal of general virology.

[74]  J. Robinson,et al.  Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity , 1997, Journal of virology.

[75]  D. Montefiori,et al.  Vaccine protection by a triple deletion mutant of simian immunodeficiency virus , 1996, Journal of virology.

[76]  R. Bronson,et al.  Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. , 1995, Science.

[77]  R. Ahmed,et al.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.

[78]  R. Desrosiers,et al.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. , 1992, Science.

[79]  R. Desrosiers,et al.  Complex determinants of macrophage tropism in env of simian immunodeficiency virus , 1992, Journal of virology.

[80]  Philip R. Johnson,et al.  HIV vaccine design: insights from live attenuated SIV vaccines , 2005, Nature Immunology.

[81]  S. Roth One step forwards, one step backwards, one step forwards: the impact of EU policy on gender relations in Central and Eastern Europe , 2004 .

[82]  Stellbrink et al SIVmac pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans, , 2003 .

[83]  R. Desrosiers,et al.  Recombinant simian immunodeficiency virus expressing green fluorescent protein identifies infected cells in rhesus monkeys. , 1999, AIDS research and human retroviruses.

[84]  R. Desrosiers,et al.  Resistance of neonatal monkeys to live attenuated vaccine strains of simian immunodeficiency virus , 1997, Nature Medicine.

[85]  B. Hill The Institute of Laboratory Animal Resources. , 1961, Bio-medical purview.